Should I buy or sell Cerevel Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CERE shares. View CERE analyst ratings or view top-rated stocks .

What is Cerevel Therapeutics' stock price target for 2024?

9 Wall Street research analysts have issued 12 month price objectives for Cerevel Therapeutics' shares. Their CERE share price targets range from $22.00 to $46.00. On average, they predict the company's share price to reach $32.33 in the next year. This suggests a possible upside of 24.4% from the stock's current price. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts .

How have CERE shares performed in 2023?

Cerevel Therapeutics' stock was trading at $31.54 at the beginning of 2023. Since then, CERE stock has decreased by 17.6% and is now trading at $26.00. View the best growth stocks for 2023 here .

When is Cerevel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our CERE earnings forecast .

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.02. During the same period in the previous year, the company posted ($0.66) earnings per share.

What ETFs hold Cerevel Therapeutics' stock?

ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , iShares Neuroscience and Healthcare ETF (IBRN) and Principal Healthcare Innovators ETF (BTEC) . Harbor Health Care ETF (MEDI) .

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN) , Arena Pharmaceuticals (ARNA) , CTI BioPharma (CTIC) , Achillion Pharmaceuticals (ACHN) , Alpha Natural Resources (ANRZQ) , Cenveo (CVO) , Hess (HES) , Palatin Technologies (PTN) , Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO) .

Who are Cerevel Therapeutics' major shareholders?

Cerevel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (13.10%), Rock Springs Capital Management LP (1.40%), Adage Capital Partners GP L.L.C. (0.84%), Westfield Capital Management Co. LP (0.54%), Affinity Asset Advisors LLC (0.38%) and Avidity Partners Management LP (0.36%). Insiders that own company stock include Abraham Ceesay, Bain Capital Investors Llc, Deval L Patrick , Gabrielle Sulzberger , John Renger , Marijn E Dekkers, Mark Bodenrader, N Anthony Coles , Paul D Burgess , Perceptive Advisors Llc and Ronald C Renaud Jr . View institutional ownership trends .

How do I buy shares of Cerevel Therapeutics?

Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cerevel Therapeutics Stock Price, News & Analysis (NASDAQ:CERE)

$26.00

+0.07 (+0.27%)

(As of 12/1/2023 ET)

Compare

Today's Range: $25.28
▼
$26.15
50-Day Range: $20.27
▼
$26.36
52-Week Range: $19.59
▼
$35.98

Volume: 1.60 million shs
Average Volume: 675,409 shs
Market Capitalization: $4.69 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.33

Cerevel Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.56 Rating Score
Upside/Downside: 24.4% Upside
$32.33 Price Target
Short Interest: Bearish
9.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.10
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$145 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.52) to ($2.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

858th out of 953 stocks

Pharmaceutical Preparations Industry

416th out of 447 stocks

2.3

Analyst's Opinion

Consensus Rating
Cerevel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.33, Cerevel Therapeutics has a forecasted upside of 24.4% from its current price of $26.00.
Amount of Analyst Coverage
Cerevel Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.73% of the float of Cerevel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cerevel Therapeutics has a short interest ratio ("days to cover") of 9.4.
Change versus previous month
Short interest in Cerevel Therapeutics has recently decreased by 1.56%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cerevel Therapeutics does not currently pay a dividend.
Dividend Growth
Cerevel Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CERE.

2.3

News and Social Media Coverage

News Sentiment
Cerevel Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Cerevel Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for CERE on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerevel Therapeutics insiders have bought 5,139.49% more of their company's stock than they have sold. Specifically, they have bought $144,999,977.00 in company stock and sold $2,767,443.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Cerevel Therapeutics is held by insiders.
Percentage Held by Institutions
87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.52) to ($2.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerevel Therapeutics is -10.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerevel Therapeutics is -10.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerevel Therapeutics has a P/B Ratio of 17.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cerevel Therapeutics Stock (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CERE Stock News Headlines

November 29, 2023 | finance.yahoo.com

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

November 22, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Amylyx Pharmaceuticals Inc (AMLX)

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 20, 2023 | benzinga.com

Cerevel Therapeutics Hldg Stock (NASDAQ:CERE) Dividends: History, Yield and Dates

November 17, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Akebia Therapeutics (AKBA)

November 17, 2023 | finance.yahoo.com

Insider Sell Alert: Director N Coles Sells 22,824 Shares of Cerevel Therapeutics Holdings Inc (CERE)

November 15, 2023 | markets.businessinsider.com

Hold Rating Maintained for Cerevel Therapeutics: Potential Catalysts, High Risk Trials, and Financial Health in Focus

November 7, 2023 | msn.com

Wall Street Analysts Think Cerevel Therapeutics Holdings, Inc. (CERE) Could Surge 27.31%: Read This Before Placing a Bet

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 6, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cerevel Therapeutics Holdings (CERE), Genmab (GMAB) and BioMarin Pharmaceutical (BMRN)

November 6, 2023 | realmoney.thestreet.com

This Mid-Cap Biotech Stock Could Rise More Than 40% From Here

November 4, 2023 | finance.yahoo.com

Director Deval Patrick Sells 30,130 Shares of Cerevel Therapeutics Holdings Inc (CERE)

November 2, 2023 | finance.yahoo.com

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Q3 2023 Earnings Call Transcript

November 2, 2023 | msn.com

Cerevel Therapeutics: High Standards And Development Burden Poses Reflexivity Risks

November 1, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurocrine (NBIX), Omega Therapeutics (OMGA) and Karuna Therapeutics (KRTX)

November 1, 2023 | seekingalpha.com

Cerevel Therapeutics Holdings, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 1, 2023 | msn.com

Cerevel Therapeutics GAAP EPS of -$0.61 beats by $0.04

November 1, 2023 | finance.yahoo.com

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

November 1, 2023 | finance.yahoo.com

Cerevel Therapeutics Holdings Inc (CERE) Reports Q3 2023 Financial Results

October 20, 2023 | finance.yahoo.com

Bain Capital Investors LLC Acquires Additional Shares in Cerevel Therapeutics Holdings Inc

October 19, 2023 | benzinga.com

Director of Cerevel Therapeutics Hldg Purchased $125.00M In Stock

October 19, 2023 | benzinga.com

Cerevel Therapeutics Hldg Insider Trades Send a Signal

October 19, 2023 | msn.com

Cerevel Therapeutics says Perceptive Advisors buys 876.8K shares

October 13, 2023 | finance.yahoo.com

Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

October 11, 2023 | finance.yahoo.com

Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock

October 11, 2023 | seekingalpha.com

Cerevel Therapeutics starts public offering of $400M of shares

October 10, 2023 | tmcnet.com

Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors

See More Headlines

Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Coal & Consumable Fuels
Sector: Medical
Current Symbol: NASDAQ:CERE
CUSIP: 15677310
CIK: 767884
Web: ceres.net
Phone: 844-304-2048
Fax: N/A
Employees: 321
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.33
High Stock Price Target: $46.00
Low Stock Price Target: $22.00
Potential Upside/Downside: +24.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.56
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-351,510,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -99.72%
Return on Assets: -42.90%

Debt

Debt-to-Equity Ratio: 1.23
Current Ratio: 8.72
Quick Ratio: 8.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.51 per share
Price / Book: 17.22

Miscellaneous

Outstanding Shares: 180,280,000
Free Float: 171,084,000
Market Cap: $4.69 billion
Optionable: Not Optionable
Beta: 1.38

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. N. Anthony Coles Jr. (Age 63)
M.P.H., Executive Chairman
Comp: $1.14M
Mr. Mark Bodenrader (Age 50)
VP of Finance & Chief Accounting Officer
Comp: $496.17k
Dr. John J. Renger Ph.D. (Age 54)
Chief Scientific Officer
Comp: $779.75k
Dr. Ramiro Sanchez M.D. (Age 62)
Chief Medical Officer
Comp: $805.13k
Mr. Ronald C. Renaud Jr. (Age 54)
M.B.A., President, CEO & Director
Dr. Susan Altschuller M.B.A. (Age 41)
Ph.D., Chief Financial Officer
Mr. Matthew Calistri
Vice President of Investor Relations
Mr. Scott M. Akamine J.D. (Age 38)
Chief Legal Officer & Corporate Secretary
Comp: $444.74k
Mr. Kenneth A. DiPietro (Age 64)
Chief Human Resources Officer
Ms. Kathleen Tregoning M.A. (Age 52)
Chief Corporate Affairs Officer
Comp: $600.79k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERE Stock Analysis - Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CERE shares.
View CERE analyst ratings or view top-rated stocks.
What is Cerevel Therapeutics' stock price target for 2024?: 9 Wall Street research analysts have issued 12 month price objectives for Cerevel Therapeutics' shares. Their CERE share price targets range from $22.00 to $46.00. On average, they predict the company's share price to reach $32.33 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for CERE or view top-rated stocks among Wall Street analysts.
How have CERE shares performed in 2023?: Cerevel Therapeutics' stock was trading at $31.54 at the beginning of 2023. Since then, CERE stock has decreased by 17.6% and is now trading at $26.00.
View the best growth stocks for 2023 here.
When is Cerevel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our CERE earnings forecast.
How were Cerevel Therapeutics' earnings last quarter?: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.02. During the same period in the previous year, the company posted ($0.66) earnings per share.

What ETFs hold Cerevel Therapeutics' stock?: ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN) and Principal Healthcare Innovators ETF (BTEC).Harbor Health Care ETF (MEDI).
What other stocks do shareholders of Cerevel Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).
Who are Cerevel Therapeutics' major shareholders?: Cerevel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (13.10%), Rock Springs Capital Management LP (1.40%), Adage Capital Partners GP L.L.C. (0.84%), Westfield Capital Management Co. LP (0.54%), Affinity Asset Advisors LLC (0.38%) and Avidity Partners Management LP (0.36%). Insiders that own company stock include Abraham Ceesay, Bain Capital Investors Llc, Deval L Patrick, Gabrielle Sulzberger, John Renger, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc and Ronald C Renaud Jr.
View institutional ownership trends.
How do I buy shares of Cerevel Therapeutics?: Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CERE) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial